NASDAQ:ZSAN - Zosano Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.17
  • Forecasted Upside: 104.40 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.06
▼ -0.01 (-0.93%)
1 month | 3 months | 12 months
Get New Zosano Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZSAN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZSAN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$2.17
▲ +104.40% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Zosano Pharma in the last 3 months. The average price target is $2.17, with a high forecast of $2.50 and a low forecast of $2.00. The average price target represents a 104.40% upside from the last price of $1.06.
Buy
The current consensus among 3 investment analysts is to buy stock in Zosano Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2021Maxim GroupBoost Price TargetBuy$1.50 ➝ $2.50N/A
i
3/15/2021Maxim GroupBoost Price TargetBuy$1.50 ➝ $2.50Low
i
11/25/2020HC WainwrightLower Price TargetBuy$2.50 ➝ $2.00Low
i
10/22/2020BTIG ResearchLower Price TargetBuy$7.00 ➝ $2.00Low
i
10/2/2020Maxim GroupReiterated RatingBuy$2.00Low
i
10/2/2020HC WainwrightLower Price TargetBuy$4.00 ➝ $2.50Low
i
Rating by R. Selvaraju at HC Wainwright
6/15/2020HC WainwrightReiterated RatingBuy$4.00High
i
Rating by R. Selvaraju at HC Wainwright
5/20/2020Maxim GroupReiterated RatingBuyMedium
i
Rating by Anthony Vendetti at Maxim Group
5/15/2020HC WainwrightReiterated RatingBuy$4.00Medium
i
Rating by R. Selvaraju at HC Wainwright
4/19/2020HC WainwrightInitiated CoverageBuy$4.00Low
i
Rating by R. Selvaraju at HC Wainwright
4/9/2020HC WainwrightInitiated CoverageBuy$4.00High
i
Rating by R. Selvaraju at HC Wainwright
3/28/2020Maxim GroupReiterated RatingBuy$2.00Low
i
Rating by Anthony Vendetti at Maxim Group
3/27/2020BTIG ResearchLower Price TargetBuy$16.00 ➝ $7.00Medium
i
3/7/2020Maxim GroupReiterated RatingBuy$2.00High
i
Rating by Anthony Vendetti at Maxim Group
11/15/2019Maxim GroupReiterated RatingBuy$8.00Low
i
11/15/2019Cantor FitzgeraldLower Price TargetOverweight$12.00 ➝ $6.00Low
i
11/15/2019BTIG ResearchLower Price TargetBuy ➝ In-Line$16.00High
i
4/22/2019Cantor FitzgeraldInitiated CoverageOverweight$3.66High
i
Rating by C. Duncan at Cantor Fitzgerald
4/17/2019Maxim GroupInitiated CoverageBuy ➝ Buy$8.00High
i
9/26/2018BTIG ResearchSet Price TargetBuy$19.00N/A
i
Rating by Robert Hazlett at BTIG Research
6/28/2018BTIG ResearchInitiated CoverageBuyHigh
i
3/24/2017Piper Jaffray CompaniesInitiated CoverageOverweight$80.00Low
i
3/11/2017Roth CapitalSet Price TargetBuy$60.00Medium
i
Rating by Scott Henry at Roth Capital
2/14/2017Roth CapitalSet Price TargetBuy$40.00 ➝ $60.00N/A
i
Rating by Scott Henry at Roth Capital
8/11/2016LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralN/A
i
(Data available from 4/14/2016 forward)
Zosano Pharma logo
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its intracutaneous microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Read More

Today's Range

Now: $1.06
$1.05
$1.07

50 Day Range

MA: $1.25
$1.07
$1.48

52 Week Range

Now: $1.06
$0.33
$3.06

Volume

18,607 shs

Average Volume

10,582,704 shs

Market Capitalization

$112.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Zosano Pharma?

The following Wall Street sell-side analysts have issued research reports on Zosano Pharma in the last twelve months: BTIG Research, HC Wainwright, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for ZSAN.

What is the current price target for Zosano Pharma?

3 Wall Street analysts have set twelve-month price targets for Zosano Pharma in the last year. Their average twelve-month price target is $2.17, suggesting a possible upside of 102.5%. Maxim Group has the highest price target set, predicting ZSAN will reach $2.50 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $2.00 for Zosano Pharma in the next year.
View the latest price targets for ZSAN.

What is the current consensus analyst rating for Zosano Pharma?

Zosano Pharma currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZSAN will outperform the market and that investors should add to their positions of Zosano Pharma.
View the latest ratings for ZSAN.

What other companies compete with Zosano Pharma?

How do I contact Zosano Pharma's investor relations team?

Zosano Pharma's physical mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company's listed phone number is 510-745-1200 and its investor relations email address is [email protected] The official website for Zosano Pharma is www.zosanopharma.com.